🦋 Graves' Disease Antithyroid Drug Simulator

Baseline Graves' Hyperthyroidism

Autoantibodies overdrive the thyroid, flooding the body with hormone.

• 4.6: Free T4 (baseline) (ng/dL, markedly high)
• 100%: TPO activity (unchecked iodination)
• Suppressed: TSH (negative feedback)
• ~1%: Prevalence (lifetime, women > men)

TSH-receptor antibodies

Autoantibodies mimic TSH, continuously stimulating the thyroid gland.

TPO-driven iodination

Thyroid peroxidase oxidizes iodide and attaches it to thyroglobulin tyrosines.

Clinical picture

Tachycardia, weight loss, heat intolerance, and tremor result from excess hormone.

Untreated Graves' disease can progress to thyroid storm, a medical emergency.

Antithyroid Drug Administered

Thionamide molecules enter the follicle and seek out TPO enzymes.

• Thionamide: Drug class (methimazole / PTU)
• TPO enzyme: Target (active-site inhibitor)
• Faster: Onset (methimazole) (longer half-life)
• Slower: Onset (PTU) (also blocks T4→T3)

Mechanism of inhibition

Drug molecules are oxidized by TPO, consuming the enzyme's catalytic capacity.

Dose dependence

Higher doses saturate more TPO molecules, blocking hormone synthesis faster.

Methimazole vs PTU

PTU also blocks peripheral T4-to-T3 conversion; methimazole is more potent overall.

Hormone Synthesis Progressively Blocked

With TPO inhibited, stored hormone depletes and free T4 declines over weeks.

• 6–8 wks: Time to euthyroid (typical course)
• ~7 days: T4 half-life (gradual decline)
• Depleting: Colloid store (no new hormone made)
• Ongoing: Titration (dose adjusted to labs)

Depleting the reservoir

Existing stored hormone in colloid is released even as new synthesis halts.

Lab-guided titration

Free T4 and TSH are rechecked periodically to fine-tune the dose.

Symptom resolution

Heart rate, tremor, and weight trends normalize as hormone falls.

Agranulocytosis Surveillance

Routine blood counts watch for a rare but dangerous neutrophil crash.

• ~0.3%: Agranulocytosis risk (of treated patients)
• <500: Danger threshold (neutrophils/µL)
• First 90 days: Onset window (highest risk period)
• Stop drug: Action if crossed (immediate discontinuation)

What to watch for

Sore throat and fever are the classic warning symptoms to report urgently.

Dose-risk relationship

Higher doses correlate with steeper, faster neutrophil declines.

Response protocol

Drug is stopped immediately and counts are monitored until recovery.

A neutrophil count under 500/µL is a medical emergency requiring drug cessation.

Outcome — Euthyroid State or Escalation

Most patients stabilize on therapy; some need definitive treatment instead.

• ~40-50%: Remission rate (after 12-18 month course)
• ~50%: Relapse rate (after stopping drug)
• RAI / surgery: Alternative (if adverse effects)
• Euthyroid: Goal (normal T4 and TSH)

Successful maintenance

Continued low-dose therapy keeps hormone levels in the normal range.

When to escalate

Agranulocytosis or poor control prompts a switch to RAI or surgery.

Long-term outlook

Many patients eventually taper off with sustained remission.

Definitive treatment options